AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, … Read more
Market Cap & Net Worth: AmCad BioMed Corporation (4188)
AmCad BioMed Corporation (TWO:4188) has a market capitalization of $18.70 Million ($U823.33 Million) as of March 18, 2026. Listed on the TWO stock exchange, this Ireland-based company holds position #28632 globally and #9 in its home market, demonstrating a -1.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AmCad BioMed Corporation's stock price $U13.00 by its total outstanding shares 63332900 (63.33 Million).
AmCad BioMed Corporation Market Cap History: 2015 to 2026
AmCad BioMed Corporation's market capitalization history from 2015 to 2026. Data shows change from $41.80 Million to $18.70 Million (-7.75% CAGR).
AmCad BioMed Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AmCad BioMed Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.69x
AmCad BioMed Corporation's market cap is 0.69 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $27.76 Million | $63.94 Million | -$35.44 Million | 0.43x | N/A |
| 2021 | $27.83 Million | $85.79 Million | -$25.54 Million | 0.32x | N/A |
| 2022 | $22.94 Million | $61.63 Million | -$53.49 Million | 0.37x | N/A |
| 2023 | $38.40 Million | $65.26 Million | -$45.31 Million | 0.59x | N/A |
| 2024 | $32.14 Million | $53.10 Million | -$50.58 Million | 0.61x | N/A |
| 2025 | $21.14 Million | $30.44 Million | -$55.72 Million | 0.69x | N/A |
Competitor Companies of 4188 by Market Capitalization
Companies near AmCad BioMed Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to AmCad BioMed Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #79 globally with a market cap of $190.05 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #153 globally with a market cap of $121.18 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #169 globally with a market cap of $112.92 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #191 globally with a market cap of $103.18 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #79 | Abbott Laboratories | NYSE:ABT | $190.05 Billion | $109.95 |
| #153 | Stryker Corporation | NYSE:SYK | $121.18 Billion | $349.56 |
| #169 | Medtronic PLC | NYSE:MDT | $112.92 Billion | $88.24 |
| #191 | Boston Scientific Corp | NYSE:BSX | $103.18 Billion | $69.79 |
AmCad BioMed Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, AmCad BioMed Corporation's market cap moved from $41.80 Million to $ 18.70 Million, with a yearly change of -7.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $U18.70 Million | -11.56% |
| 2025 | $U21.14 Million | -34.23% |
| 2024 | $U32.14 Million | -16.29% |
| 2023 | $U38.40 Million | +67.40% |
| 2022 | $U22.94 Million | -17.57% |
| 2021 | $U27.83 Million | +0.26% |
| 2020 | $U27.76 Million | -20.25% |
| 2019 | $U34.80 Million | -11.68% |
| 2018 | $U39.40 Million | -2.14% |
| 2017 | $U40.27 Million | -8.50% |
| 2016 | $U44.01 Million | +5.28% |
| 2015 | $U41.80 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of AmCad BioMed Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.70 Million USD |
| MoneyControl | $18.70 Million USD |
| MarketWatch | $18.70 Million USD |
| marketcap.company | $18.70 Million USD |
| Reuters | $18.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.